NCT04889950View on ClinicalTrials.gov

Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 26, 2021

Primary Completion Date

January 4, 2023

Study Completion Date

February 8, 2023

Conditions
Dry Eye SyndromesDry EyeMeibomian Gland Dysfunction
Interventions
DEVICE

Tixel C

Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.

DEVICE

LipiFlow

LipiFlow

Trial Locations (1)

9103102

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors
lead

Novoxel Ltd.

INDUSTRY

NCT04889950 - Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction | Biotech Hunter | Biotech Hunter